Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Cannabis Science Inc (CBIS)

OTC Markets
Currency in USD
0.0505
0.0000(0.00%)
Closed
Fair Value
Day's Range
0.05010.0540
52 wk Range
0.00000.0540
Key Statistics
Edit
Prev. Close
0.0505
Open
0.0524
Day's Range
0.0501-0.054
52 wk Range
0-0
Volume
-
Average Vol. (3m)
34.09M
1-Year Change
930.61%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CBIS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Currently not supported.
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Cannabis Science Inc Company Profile

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, benefits of medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. Further, it operates an industrial hemp research and development project. It has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug; and a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to develop and investigate the use of cannabinoids to cure various cancers, as well as with Stellenbosch University to treat chronic pelvic pain associated with pelvic inflammatory disease in women, chronic prostatitis in men, and other chronic pain associated with other indications. Cannabis Science, Inc. also has a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to investigate the use of extract from the Justicia plant to treat blood disorders. The company was formerly known as Gulf Onshore, Inc. and changed its name to Cannabis Science, Inc. in April 2009. The company was incorporated in 1996 and is based in Irvine, California. Cannabis Science, Inc. operates as a subsidiary of Weedmaps Media, Inc.

Employees
1

Compare CBIS to Peers and Sector

Metrics to compare
CBIS
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price / Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.